Wednesday, May 27, 2015

EyewireTV — Omidria Recommendation, Pediatric Visual Impairment Study

In this week’s EyewireTV, a month after the commercial launch of Omidria (phenylephrine and ketorolac injection 1%/0.3%) in the United States, European drug regulators have recommended the agent for use during lens replacement surgery; and a large British study of children aged 7 to 9 finds that visual impairment is rarely the cause of pediatric reading problems. Also, Nidek launches the GYC-500 Vixi Green Scan/GYC-500 Green Laser photocoagulator. (1697 Views)

Watch Video

Wednesday, May 20, 2015

Phase 3 Dry Eye Drug Candidate Results, Fovista Update

In this week's EyewireTV, Eleven Biotherapeutics announces that its lead dry eye drug candidate (EBI-005) did not meet either of the two coprimary endpoints in a phase 3 study; and Ocular Therapeutix plans to submit a new drug application to the FDA for its postsurgical ocular pain drug candidate OTX-DP (Dextenza). Also, Ophthotech provides an update and timing projections on its Fovista phase 3 program, which consists of three clinical trials to evaluate the safety and efficacy of Fovista for the treatment of wet AMD. (1865 Views)

Watch Video

Wednesday, May 13, 2015

EyewireTV — Ebola Virus in Eye, AMO iDesign Clearance

In this week's EyewireTV, a report published online in the New England Journal of Medicine reveals that the Ebola virus remained live in the aqueous humor of an Ebola survivor for more than 2 months after recovery; and Abbott Medical Optics receives FDA clearance for the iDesign Advanced Wavescan Studio system for use in LASIK procedures. Also, Regeneron reports that sales of its blockbuster drug Eylea (aflibercept) increased 51% in the United States to $541 million in the first quarter of 2015. (2392 Views)

Watch Video

Wednesday, May 06, 2015

EyewireTV — Ophthalmic Executives Provide Company Updates

In this week's EyewireTV, several executives at the Ophthalmology Innovation Summit in San Diego speak to EyewireTV about the main product candidates in their companies' pipelines. (2093 Views)

Watch Video

Wednesday, April 29, 2015

EyewireTV — Rhopressa Misses Phase 3 Endpoint, Shire CEO Interview

In this week's EyewireTV, Aerie Pharmaceuticals reports that its phase 3 trial of once-daily Rhopressa did not meet its primary efficacy endpoint of demonstrating noninferiority of IOP-lowering compared with twice-daily timolol; and the FDA clears the mVT Service, the first ophthalmic app designed to monitor AMD and diabetic retinopathy. In the feature, Flemming Ornskov, MD, chief executive officer of Shire, talks about the company’s increased focus on the ophthalmology market and the potential for lifitegrast to address an unmet need in the dry eye space. (2410 Views)

Watch Video

Wednesday, April 22, 2015

EyewireTV — Industry News Roundup From the ASCRS Meeting in San Diego

In this week's EyewireTV, AcuFocus receives FDA approval for the Kamra inlay for the surgical correction of presbyopia; and Alcon releases a software upgrade for the LenSx laser system that allows for customized flap creation. Also, Abbott Medical Optics launches a new phaco system called the Compact Intuitiv. (3884 Views)

Watch Video

Tuesday, April 14, 2015

EyewireTV — Lifitegrast Priority Review, Launch

In this week's EyewireTV, Shire achieves a key milestone as the FDA grants priority review designation for the company's dry eye treatment candidate, lifitegrast; and, an online marketplace designed to allow practitioners to learn, compare, rate, and purchase eye care technology, launches. Also, Ellex Medical introduces its multicolor scanning photocoagulator, Integre Pro Scan, in the United States. (2222 Views)

Watch Video

Wednesday, April 08, 2015

EyewireTV — Omidria Launch, Phase 3 Postoperative Product Candidate Results

In this week's EyewireTV, Omeros announces the commercial launch in the United States of its lead eye drug Omidria (phenylephrine and ketorolac injection 1%/0.3%); and in a second phase 3 study, Ocular Therapeutix's product candidate, OTX-DP (sustained-release dexamethasone 0.4mg), meets the primary endpoint of absence of pain, but does not meet the primary endpoint of absence of inflammation. Also, Kala Pharmaceuticals announces positive top-line results from the phase 3 evaluation of its postoperative pain and inflammation drug candidate, KPI-121 (nanoparticle loteprednol etabonate MPP). (2193 Views)

Watch Video

Wednesday, April 01, 2015

EyewireTV — Avedro CXL FDA Application Not Approved, Eylea New Indication

In this week's EyewireTV, the FDA decides not to approve Avedro’s new drug application for its corneal cross-linking platform, identifying areas of the application concerning the device that require additional information; and Lensar receives FDA clearance of five new performance upgrades, collectively called the Streamline advanced technology suite, to its Lensar Laser System. Also, the FDA expands the indication of Regeneron’s Eylea (aflibercept) to treat diabetic retinopathy in patients with diabetic macular edema. (2813 Views)

Watch Video

Wednesday, March 25, 2015

EyewireTV — Actavis Completes Allergan Acqusition, EVA FDA Approval

In this week's EyewireTV, Actavis completes its acquisition of Allergan in a transaction valued at about $70.5 billion in cash and equity; and DORC receives FDA approval for the EVA integrated vitrectomy and phaco system. In the feature, leading ophthalmologists discuss how private practices and academic programs affect drug and product innovation. (2323 Views)

Watch Video

Wednesday, March 18, 2015

New Clinical Findings for Cataract and Glaucoma Drug Candidates

In this week’s EyewireTV, Ocular Therapeutix announces positive topline data from a phase 3a clinical trial evaluating the safety and efficacy of its drug candidate, OTX-DP, for the treatment of ocular inflammation and pain following cataract surgery; and preclinical research by Aerie Pharmaceuticals shows that the company’s lead drug candidate, Rhopressa, has the potential to modify the course of glaucoma by arresting fibrosis. (1930 Views)

Watch Video

Wednesday, March 11, 2015

EyewireTV - LessDrops Evaluation Results, US Drug Spending Soars

In this week's EyewireTV, Imprimis Pharmaceuticals and the Cleveland Eye Clinic announce preliminary results of an investigator-initiated evaluation examining the use of the company's proprietary LessDrops formulation; and Drug spending in the United States rose last year at the fastest rate in more than a decade, driven by soaring demand and price increases for specialty agents. Also, Carl Zeiss Meditec launches its next-generation perimetry system, the Humphrey Field Analyzer 3. (2802 Views)

Watch Video
Load More